Results

CDC - Centers for Disease Control and Prevention

11/15/2019 | Press release | Distributed by Public on 11/15/2019 10:27

Weekly U.S. Influenza Surveillance Report

Clinical Laboratories

Due to technical issues with the National Respiratory and Enteric Virus Surveillance System (NREVSS) reporting platform, the clinical laboratory data are not available for week 45. An update to previous weeks is included in the table below and is available on FluView Interactive. Reporting of this data will resume once the technical issues have been resolved. We apologize for the inconvenience.

Week 45 Cumulative Data
September 29, 2019 through
November 2, 2019
(Weeks 40 - 44)
No. of specimens tested -- 104,888
No. of positive specimens (%) -- 2,091 (2.0%)
Positive specimens by type
Influenza A -- 793 (37.9%)
Influenza B -- 1,298 (62.1%)

Public Health Laboratories

The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage.

Week 45 Data Cumulative since
September 29, 2019
(week 40)
No. of specimens tested 844 6,473
No. of positive specimens 178 1,185
Positive specimens by type/subtype
Influenza A 73 (41.0%) 627 (52.9%)
(H1N1)pdm09 40 (61.5%) 223 (39.3%)
H3N2 25 (38.5%) 344 (60.7%)
Subtyping not performed 8 60
Influenza B 105 (59.0%) 558 (47.1%)
Yamagata lineage 5 (7.0%) 17 (4.0%)
Victoria lineage 66 (93.0%) 408 (96.0%)
Lineage not performed 34 133

Nationally influenza B/Victoria viruses have been reported more frequently than other influenza viruses this season; however, influenza A(H3N2) and A(H1N1)pdm09 viruses are also circulating widely. The predominant virus varies by region. Regional and state level data about circulating influenza viruses can be found on FluView Interactive. The predominant virus also varies by age group. Nationally, influenza B/Victoria viruses are the most commonly reported influenza viruses among children age 0-4 years (45% of reported viruses) and 5-24 years (53% of reported viruses), while A(H3N2) viruses are the most commonly reported influenza viruses among persons 65 years of age and older (72% of reported viruses). Among adults aged 25-64 years, approximately equal proportions of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses (31%, 30% and 26%, respectively) have been reported. Additional age data can be found on FluView Interactive.

For additional virologic surveillance information for this season and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

CDC performs genetic and antigenic characterization of U.S. viruses submitted from state and local health laboratories using Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses used for developing new influenza vaccines and to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.

Virus characterization data will be updated starting later this season when sufficient numbers of specimens have been tested.


ILINet

Nationwide during week 45, 2.3% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is below the national baseline of 2.4%.

On a regional level, the percentage of outpatient visits for ILI ranged from 1.2% to 4.2% during week 45. Region 4 (Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee), Region 6 (Arkansas, Louisiana, New Mexico, Oklahoma, and Texas), Region 7 (Iowa, Kansas, Missouri, and Nebraska), and Region 9 (Arizona, California, Hawaii, and Nevada) reported a percentage of outpatient visits for ILI which is equal to or above their region-specific baselines. Regions 1, 2, 3, 5, 8, and 10 remained below their region-specific baselines.

ILI Activity Map

Data collected in ILINet are used to produce a measure of ILI activity* by state.

During week 45, the following ILI activity levels were experienced:

  • High - one state (Louisiana)
  • Moderate - Puerto Rico and five states (Alabama, Georgia, Mississippi, South Carolina and Texas)
  • Low - nine states (Arizona, Arkansas, Connecticut, Missouri, Nevada, New Mexico, Oklahoma, Tennessee and Virginia)
  • Minimal - the District of Columbia, New York City, and 35 states (Alaska, California, Colorado, Delaware, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, South Dakota, Utah, Vermont, Washington, West Virginia, Wisconsin and Wyoming)
  • Data were Insufficient to calculate an ILI activity level from the U.S. Virgin Islands.

Additional information about medically attended visits for ILI this season and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

The influenza activity reported by state and territorial epidemiologists indicates geographic spread of influenza viruses but does not measure the severity of influenza activity.

During week 45 the following influenza activity was reported:

  • Widespread - three states (California, Louisiana and Maryland)
  • Regional - seven states (Alabama, Florida, Indiana, Nevada, New Hampshire, Tennessee and Texas)
  • Local - Puerto Rico and 20 states (Arizona, Colorado, Connecticut, Georgia, Hawaii, Illinois, Iowa, Kentucky, Massachusetts, Mississippi, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, South Carolina, Virginia and Washington)
  • Sporadic - the District of Columbia, the U.S. Virgin Islands and 19 states (Alaska, Arkansas, Delaware, Idaho, Kansas, Maine, Michigan, Minnesota, Missouri, Montana, Nebraska, Ohio, Pennsylvania, South Dakota, Utah, Vermont, West Virginia, Wisconsin and Wyoming)
  • No Activity - one state (Rhode Island)
  • Guam did not report.

Additional information about the geographic spread of influenza this season and past seasons:
Surveillance Methods | FluView Interactive

The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in the Emerging Infections Program (EIP) states and Influenza Hospitalization Surveillance Project (IHSP) states. FluSurv-NET estimated hospitalization rates will be updated weekly starting later this season when a sufficient number of hospitalizations have been reported.

Additional FluSurv-NET data can be found at: http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html and http://gis.cdc.gov/grasp/fluview/FluHospChars.html.

Based on National Center for Health Statistics (NCHS) mortality surveillance data available on November 14, 2019, 4.9% of the deaths occurring during the week ending October 19, 2019 (week 44) were due to P&I. This percentage is below the epidemic threshold of 6.0% for week 44.

Additional pneumonia and influenza mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive

Two influenza-associated pediatric deaths were reported to CDC during week 45.

One death was associated with an influenza A virus for which no subtyping was performed and occurred during week 7 (the week ending February 16, 2019) in the 2018-2019 season. This brings the total number of deaths during that season to 143.

One death was associated with an influenza B/Victoria virus and occurred during week 44 (the week ending November 2, 2019). A total of three influenza-associated pediatric deaths occurring during the 2019-2020 season have been reported to CDC.

Additional Influenza-associated pediatric mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive

Additional National and International Influenza Surveillance Information

FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics. To access these tools, visit http://www.cdc.gov/flu/weekly/fluviewinteractive.htm

National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH at https://www.cdc.gov/niosh/topics/absences/default.html

U.S. State and local influenza surveillance: Click on a jurisdiction below to access the latest local influenza information

World Health Organization: Additional influenza surveillance information from participating WHO member nations is available through FluNet and the Global Epidemiology Reports.

WHO Collaborating Centers for Influenza located in Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia).

Europe: For the most recent influenza surveillance information from Europe, please see WHO/Europe and the European Centre for Disease Prevention and Control at http://www.flunewseurope.org/.

Public Health Agency of Canada: The most up-to-date influenza information from Canada is available at http://www.phac-aspc.gc.ca/fluwatch/

Public Health England: The most up-to-date influenza information from the United Kingdom is available at https://www.gov.uk/government/statistics/weekly-national-flu-reports

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at: http://www.cdc.gov/flu/weekly/overview.htm.


--------------------------------------------------------------------------------